LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

Fulgent Genetics Inc

Chiusa

SettoreSettore sanitario

21.94 0.05

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

21.56

Massimo

22.27

Metriche Chiave

By Trading Economics

Entrata

-7.4M

-19M

Vendite

8.3M

82M

Margine di Profitto

-23.539

Dipendenti

1,313

EBITDA

-3.5M

-15M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+15.45% upside

Dividendi

By Dow Jones

Utili prossimi

7 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

124M

673M

Apertura precedente

21.89

Chiusura precedente

21.94

Notizie sul Sentiment di mercato

By Acuity

50%

50%

167 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Fulgent Genetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 set 2025, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 set 2025, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 set 2025, 21:59 UTC

Utili

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 set 2025, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

17 set 2025, 23:39 UTC

Discorsi di Mercato

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 set 2025, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 set 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 set 2025, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 set 2025, 21:00 UTC

Utili

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 set 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

17 set 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 19:59 UTC

Discorsi di Mercato

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 set 2025, 19:07 UTC

Discorsi di Mercato

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 set 2025, 18:43 UTC

Discorsi di Mercato

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 set 2025, 18:38 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 set 2025, 18:20 UTC

Discorsi di Mercato

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 18:18 UTC

Discorsi di Mercato

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 set 2025, 18:14 UTC

Discorsi di Mercato

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 set 2025, 17:59 UTC

Discorsi di Mercato

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 set 2025, 17:15 UTC

Acquisizioni, Fusioni, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 set 2025, 17:06 UTC

Acquisizioni, Fusioni, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 set 2025, 16:51 UTC

Utili

Correct: Exor 1H Net Loss -EUR624M

17 set 2025, 16:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 set 2025, 16:34 UTC

Discorsi di Mercato

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 set 2025, 16:25 UTC

Utili

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 set 2025, 16:23 UTC

Utili

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Confronto tra pari

Modifica del prezzo

Fulgent Genetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

15.45% in crescita

Previsioni per 12 mesi

Media 25.33 USD  15.45%

Alto 30 USD

Basso 21 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Fulgent Genetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

17.32 / 19.04Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

167 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Fulgent Genetics Inc

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.
help-icon Live chat